Class Action Lawsuit Against Cassava Sciences, Inc.
Pomerantz LLP has filed a class action lawsuit against Cassava Sciences, Inc. (NASDAQ: SAVA), urging shareholders who have faced losses to take action. Investors who purchased or acquired Cassava securities during the relevant Class Period should consider their options.
The Allegations Against Cassava
The lawsuit focuses on allegations that Cassava and its executives may have engaged in improper practices related to securities. This raises concerns of potential fraud and misrepresentation, significantly affecting investor trust.
Crucial Deadlines for Shareholders
All shareholders affected by this situation should take note: there is an important deadline approaching. Stakeholders have until February 10, 2025, to apply to the Court as a Lead Plaintiff in the lawsuit. It is essential for investors to act promptly to protect their interests in Cassava Sciences.
Impact of Recent Drug Trial Results
On November 25, 2024, Cassava announced devastating news regarding its drug, simufilam, which failed to clear the necessary benchmarks in a critical Phase 3 trial designed to evaluate its effectiveness for mild-to-moderate Alzheimer’s disease. Following this disappointing revelation, the company also announced the discontinuation of a second Phase 3 trial that had been examining both 100 mg and 50 mg tablet dosages.
Stock Price Repercussions
The fallout from the drug trial results was severe, with Cassava's stock price plummeting by a staggering 83.78%. The share price dropped from $22.19 to just $4.30 per share on the same day the announcement was made. This significant decline has, understandably, led many investors to reevaluate their positions.
About Pomerantz LLP
Pomerantz LLP is a well-respected law firm known for its expertise in corporate, securities, and antitrust class litigation. With a legacy of over 85 years, the firm was founded by the esteemed legal figure Abraham L. Pomerantz. His commitment to championing the rights of victims of securities fraud continues to be the firm's guiding mission. Pomerantz has successfully achieved billions in damages for class members across various high-profile cases.
Contact Information for Investors
For investors seeking more information or wishing to discuss their situation regarding Cassava Sciences, they can reach out to Danielle Peyton at the firm. Those interested in joining the class action are encouraged to provide their contact details and relevant purchasing information.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit pertains to allegations of securities fraud and unlawful practices by Cassava Sciences and its leadership.
Who should join the class action?
Shareholders of Cassava Sciences who experienced losses due to the company’s actions or its failed drug trials should consider joining the class action.
When is the deadline to become a Lead Plaintiff?
The deadline to apply as Lead Plaintiff in the lawsuit is February 10, 2025.
What were the results of the Phase 3 trial?
The Phase 3 trial of simufilam failed to meet critical endpoints, leading to the discontinuation of the study.
How has Cassava's stock been affected?
Following the trial results announcement, Cassava's stock price fell dramatically, dropping over 80% in a single day.
